Clinical assessment of 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan (FOLFIRABRAX) in untreated gastrointestinal cancer patients using UGT1A1 genotype-guided dosing

PURPOSE: 5-fluorouracil/leucovorin, irinotecan, and nab-paclitaxel are all active agents in gastrointestinal cancers; the combination, FOLFIRABRAX, has not been previously evaluated. UDP Glucuronosyltransferase 1A1 (UGT1A1) clears SN-38, the active metabolite of irinotecan. UGT1A1*28 polymorphism re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Joshi, Smita S., Catenacci, Daniel V.T., Karrison, Theodore G., Peterson, Jaclyn D., Zalupski, Mark M., Sehdev, Amikar, Wade, James, Sadiq, Ahad, Picozzi, Vincent, Amico, Andrea, Marsh, Robert, Kozloff, Mark F., Polite, Blase N., Kindler, Hedy L., Sharma, Manish R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942629/
https://ncbi.nlm.nih.gov/pubmed/31558477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1483
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky